JPWO2020055932A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020055932A5
JPWO2020055932A5 JP2021512883A JP2021512883A JPWO2020055932A5 JP WO2020055932 A5 JPWO2020055932 A5 JP WO2020055932A5 JP 2021512883 A JP2021512883 A JP 2021512883A JP 2021512883 A JP2021512883 A JP 2021512883A JP WO2020055932 A5 JPWO2020055932 A5 JP WO2020055932A5
Authority
JP
Japan
Prior art keywords
csf
hgm
antibody
pharmaceutical composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517461A (ja
JP2022517461A5 (https=
Publication date
Priority claimed from US16/149,346 external-priority patent/US10870703B2/en
Priority claimed from US16/204,220 external-priority patent/US10899831B2/en
Priority claimed from US16/248,762 external-priority patent/US10927168B2/en
Priority claimed from US16/283,694 external-priority patent/US11130805B2/en
Application filed filed Critical
Priority claimed from PCT/US2019/050494 external-priority patent/WO2020055932A2/en
Publication of JP2022517461A publication Critical patent/JP2022517461A/ja
Publication of JPWO2020055932A5 publication Critical patent/JPWO2020055932A5/ja
Publication of JP2022517461A5 publication Critical patent/JP2022517461A5/ja
Pending legal-status Critical Current

Links

JP2021512883A 2018-09-10 2019-09-10 Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 Pending JP2022517461A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862729043P 2018-09-10 2018-09-10
US62/729,043 2018-09-10
US16/149,346 US10870703B2 (en) 2017-10-02 2018-10-02 Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
PCT/US2018/053933 WO2019070680A2 (en) 2017-10-02 2018-10-02 METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING GM-CSF ANTAGONIST
USPCT/US2018/053933 2018-10-02
US16/149,346 2018-10-02
US16/204,220 2018-11-29
US16/204,220 US10899831B2 (en) 2017-10-02 2018-11-29 Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US16/248,762 US10927168B2 (en) 2017-10-02 2019-01-15 Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US16/248,762 2019-01-15
US16/283,694 2019-02-22
US16/283,694 US11130805B2 (en) 2017-10-02 2019-02-22 Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
PCT/US2019/050494 WO2020055932A2 (en) 2018-09-10 2019-09-10 Methods of treating immunotherapy-related toxicity using a gm-csf antagonist

Publications (3)

Publication Number Publication Date
JP2022517461A JP2022517461A (ja) 2022-03-09
JPWO2020055932A5 true JPWO2020055932A5 (https=) 2022-09-21
JP2022517461A5 JP2022517461A5 (https=) 2022-09-21

Family

ID=69778357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512883A Pending JP2022517461A (ja) 2018-09-10 2019-09-10 Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法

Country Status (11)

Country Link
EP (1) EP3849572A4 (https=)
JP (1) JP2022517461A (https=)
KR (1) KR20210075090A (https=)
CN (1) CN113164520A (https=)
AU (1) AU2019340662A1 (https=)
BR (1) BR112021004489A2 (https=)
CA (1) CA3111804A1 (https=)
IL (1) IL281243A (https=)
MX (1) MX2021002856A (https=)
SG (1) SG11202102317PA (https=)
WO (1) WO2020055932A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240158467A1 (en) * 2018-10-31 2024-05-16 Humanigen, Inc. Materials and methods for treating cancer
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN118949031A (zh) * 2019-06-03 2024-11-15 基尼克萨制药股份有限公司 用gm-csf拮抗剂治疗癌症
WO2021204649A1 (en) * 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN113402620B (zh) * 2021-07-30 2021-12-10 中山大学 细胞因子联合嵌合抗原受体的融合蛋白及其应用
CN116887856A (zh) * 2022-01-20 2023-10-13 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用
CN114606237B (zh) * 2022-05-11 2025-10-28 上海优替济生生物医药有限公司 Gm-csf抑制剂及其用途
CN119144563B (zh) * 2023-11-24 2025-11-25 成都赛恩吉诺生物科技有限公司 表达gm-csf截短功能区片段的免疫工程细胞及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
NZ588850A (en) * 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
LT4461308T (lt) * 2012-07-13 2025-06-10 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo valdymas
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
US20190292246A1 (en) * 2016-11-03 2019-09-26 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia imhibitor
EP3691663A4 (en) * 2017-10-02 2021-08-18 Humanigen, Inc. METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST
US10899831B2 (en) * 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
JP7411578B2 (ja) * 2018-06-01 2024-01-11 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 癌を治療するための物質及び方法

Similar Documents

Publication Publication Date Title
JP2022517461A5 (https=)
Hao et al. Macrophage, the potential key mediator in CAR-T related CRS
Lu et al. Development of therapeutic antibodies for the treatment of diseases
Reichert Antibodies to watch in 2017
Balato et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders
Isaacs et al. Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody
Umezawa et al. Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab
Khorasanizadeh et al. Efficacy and safety of benralizumab, a monoclonal antibody against IL-5Rα, in uncontrolled eosinophilic asthma
Jackson et al. Targeting the IL‐5 pathway in eosinophilic asthma: a comparison of anti‐IL‐5 versus anti‐IL‐5 receptor agents
Seluk et al. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma
Courbette et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease
CN113164520A (zh) 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
US20190284271A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
JPWO2020055932A5 (https=)
US20220378829A1 (en) Genetically engineered immune cells targeting cd70 for use in treating solid tumors
Thiele et al. Efficacy and safety of etanercept biosimilars compared with the originator for treatment of juvenile arthritis: a prospective observational study
US20210322547A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
Desai et al. Immunomodulators and biologics: beyond stepped-care therapy
Lim et al. Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials
Mok et al. Non-TNF biologics and their biosimilars in rheumatoid arthritis
US20150322519A1 (en) Biomarkers for psoriasis treatment response
Yoo et al. Targets of monoclonal antibodies for immunological diseases.
US20210290677A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
JP7475011B2 (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
JP7818747B2 (ja) 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー